Atara Biotherapeutics, Inc. (ATRA)
9.48
+1.02
(+12.06%)
USD |
NASDAQ |
Oct 02, 16:00
9.60
+0.12
(+1.27%)
After-Hours: 20:00
Atara Biotherapeutics Gross Profit Margin (Quarterly) : 69.68% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 69.68% |
| March 31, 2026 | 75.97% |
| December 31, 2025 | 93.48% |
| September 30, 2025 | 96.67% |
| June 30, 2025 | 96.85% |
| March 31, 2025 | 79.18% |
| December 31, 2024 | 79.25% |
| September 30, 2024 | 81.08% |
| June 30, 2024 | 83.84% |
| March 31, 2024 | 92.74% |
| December 31, 2023 | 25.68% |
| Date | Value |
|---|---|
| September 30, 2023 | -22.31% |
| June 30, 2023 | -636.1% |
| March 31, 2023 | -251.5% |
| December 31, 2022 | -1.74K% |
| September 30, 2022 | 7.13% |
| June 30, 2022 | 91.85% |
| March 31, 2022 | 69.58% |
| December 31, 2021 | 57.82% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 26.94% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
| Biogen, Inc. | 61.37% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -64.19% |
| Return on Invested Capital | -94.43% |
| Profit Margin (Quarterly) | -767.3% |
| Operating Margin (Quarterly) | -627.5% |
| Return on Net Operating Assets | -180.1% |